Numerous combinations of agents are used in the first-line treatment of ES-SCLC, but the optimal combination regimen remains unclear.
Dr. Li Zhang and colleagues from Sun Yat-sen University Cancer Center, in Guangzhou, China, sought to clarify which first-line combination regimen yields the best tumor response among patients with ES-SCLC in their review of three phase-2 and 11 phase-3 randomized clinical trials involving more than 4,800 patients and eight different regimens.
There was no clearly superior treatment in terms of objective response rate, but the combination of a PD-L1 inhibitor (durvalumab or atezolizumab) plus etoposide-platinum chemotherapy yielded significantly better disease control rate versus chemotherapy alone (hazard ratio, 1.40).
Bevacizumab plus etoposide-based chemotherapy provided the best progression-free survival, but this did not translate into an overall survival benefit.
The most favorable overall survival followed treatment with a PD-L1 inhibitor plus etoposide-based chemotherapy, the researchers report in JAMA Network Open.
The addition of PD-L1 inhibitors to chemotherapy caused no more toxic effects in general than did chemotherapy alone.
Among all first-line treatments for patients with SCLC, the combination of PD-L1 inhibitors plus etoposide-platinum chemotherapy had the highest chance of ranking first for disease control rate and overall survival, whereas the combination of bevacizumab plus etoposide-platinum chemotherapy had the highest chance of ranking first for progression-free survival and treatment-related adverse events of grade 3 or greater.
"These findings could provide recommendations for clinicians in selecting first-line treatments based on their clinical benefits and safety profiles," the authors conclude.
Dr. Zhang did not respond to a request for comments.
By Reuters Staff
SOURCE: https://bit.ly/35oc3Pg JAMA Network Open, online October 19, 2020.
Posted on
Previous Article
« Even mild NAFLD associated with higher mortality Next Article
Fecal transplant stops beta cell decline in newly diagnosed T1D »
« Even mild NAFLD associated with higher mortality Next Article
Fecal transplant stops beta cell decline in newly diagnosed T1D »
Related Articles
November 25, 2020
Lorlatinib outperforms crizotinib in ALK-positive advanced NSCLC
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com